

1 **Heterogeneity of the placenta in health and disease explored through integrated**
2 **histology, gene expression and modelling**

3 **Hannah Ee Juen Yong^{1,2*}, Kasia Maksym^{3,4*}, Muhammad Ashraf Bin Yusoff³, Esteban**
4 **Salazar-Petres¹, Tatiana Nazarenko^{3,5}, Alexey Zaikin^{3,5}, Anna L David^{3,4,6}, Sara L**
5 **Hillman^{3,4+}, Amanda N. Sferruzzi-Perri¹⁺**

6
7 *contributed equally; joint first author

8 +contributed equally; joint last and corresponding author

9
10 ¹Centre for Trophoblast Research,
11 Department of Physiology, Development and Neuroscience
12 University of Cambridge
13 Cambridge UK
14 CB2 3EG

15
16 ²Singapore Institute for Clinical Sciences,
17 Agency for Science, Technology and Research,
18 Singapore

19
20 ³Elizabeth Gareth Anderson Institute for Women's Health,
21 University College London,
22 84-86 Chenies Mews, London UK
23 WC1E 6HU

24 ⁴Fetal Medicine Unit
25 Elizabeth Gareth Anderson Wing,
26 University College Hospitals NHS Trust,
27 25 Grafton Way, London UK
28 WC1E 6DB

29
30 ⁵Department of Mathematics,
31 University College London,
32 London UK

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

33 WC1E 6AE

34

35 ⁶ National Institute for Health Research University College London Hospitals Biomedical

36 Research Centre, 149 Tottenham Court Road, London W1T 7DN

37

38 Correspondence:

39 Amanda Sferruzzi-Perri (ans48@cam.ac.uk)

40 Sara Hillman (sara.hillman@ucl.ac.uk)

41

42 **Abstract:**

43 Fetal growth restriction (FGR) is a leading cause of perinatal morbidity and mortality. Altered
44 placental formation and functional capacity are major contributors to FGR pathogenesis.
45 Relating placental structure to function across the placenta in healthy and FGR pregnancies
46 remains largely unexplored but could improve understanding of placental diseases. We
47 investigated integration of these parameters spatially in the term human placenta using
48 predictive modelling. Systematic sampling was able to overcome heterogeneity in placental
49 morphological and molecular features. Defects in villous development, elevated fibrosis, and
50 reduced expression of growth and functional marker genes (IGF2, VEGA, SLC38A1,
51 SLC2A3) were seen in age-matched term FGR versus healthy control placentas. Characteristic
52 histopathological changes with specific accompanying molecular signatures could be
53 integrated through computational modelling to predict if the placenta came from a healthy or
54 FGR pregnancy. Our findings yield new insights into the spatial relationship between placental
55 structure and function and the aetiology of FGR.

56

57 Key words: Placenta, FGR, modelling, morphology, growth genes, transport

58

59

60 **Introduction:**

61 The human placenta is a highly specialized organ in pregnancy, whereby normal functioning
62 is critical to fetal development and long-term health. By acting as a functional interface
63 between the maternal and fetal circulation, it is responsible for maternal-fetal substrate
64 exchange, protects the fetus from immune rejection by the mother and secretes hormones,
65 which maintain pregnancy and promote healthy fetal growth and development^{1,2}. This complex
66 organ is structurally heterogeneous, not only in terms of its broad spatial macroscopic
67 characteristics with multiple cotyledons and vascular supply, but also at the microscopic level
68 of the villous tree and trophoblast. Even in pregnancies that deliver at term without any
69 apparent pathology, novel techniques such as micro-CT are now describing the large degree of
70 heterogeneity of vascular density and branching in the placenta³. In addition, computational
71 models have predicted that local heterogeneity in placental vascular structure can have major
72 impacts on the resistance of the fetoplacental circulation and placental dysfunction⁴.
73 Investigating the spatial relationships between changes in gene expression and structural
74 differences in the placenta is important, so that we may better elucidate the potential functional
75 effect of placental pathology in obstetric disease.

76

77 Fetal growth restriction (FGR) is a major cause of perinatal morbidity and mortality. The risk
78 of *in utero* or neonatal death is especially high amongst growth restricted fetuses and neonates
79 who are commonly born preterm⁵. In some regions of the world, FGR and prematurity account
80 for 80% of neonatal deaths⁶. FGR is diagnosed when a fetus fails to reach their genetically
81 predefined growth potential and is often identified by fetoplacental ultrasound features (such
82 as increased umbilical artery resistance to blood flow), and subsequently confirmed through
83 placental histopathology⁷. The gestational age at diagnosis is used to further subdivide FGR
84 into early-onset, detected before 32 weeks of gestation, and late-onset according to
85 international consensus⁸. Neonates born following FGR have an increased risk of developing
86 health problems, both in the immediate postnatal period including low blood sugars and poor
87 temperature regulation and feeding, but also in later adult life in the form of cardiovascular and
88 metabolic disease^{9,10}. Management of pregnancies affected by FGR can be challenging, as
89 timing of delivery has to be judged well, to balance the hazards of preterm birth against the
90 risks of irreversible damage secondary to intrauterine hypoxia and nutritional deficiency or
91 even stillbirth¹¹.

92

93 The placenta of FGR pregnancies is characterized by reduced syncytiotrophoblast surface area,
94 increased thickness of the exchange barrier formed by the trophoblast and fetal capillary
95 endothelium and an increase in placental apoptosis¹²⁻¹⁵. Whilst it is recognized that there are
96 key mediators of fetal growth that are influenced by placental function including but not limited
97 to transfer of gases¹⁶, glucose^{17,18}, lipids¹⁹ and amino acids^{18,20}, understanding the mechanisms
98 through which placental histological changes might be affecting these pathways remains a
99 challenge. Nuanced, integrated investigations will better delineate the underlying functional
100 mechanisms related to the histological changes observed in the placenta. Experimental animal
101 data has highlighted central roles that certain structural and functional changes play in the
102 placenta to fetal growth outcomes²¹⁻²⁵. However, data on how structure *and* molecular changes
103 together impact on function and on each other, even in the form of nutrient transporter
104 expression, are scarce or not available for the human placenta^{26,27}.

105

106 Better understanding of how placental structure relates to functional capacity is further
107 optimized through robust placental sampling protocols. Methodological errors arise from
108 differences in sampling and/or tissue processing, which has previously hampered the
109 reproducibility and possible extrapolation of placental studies^{28,29}. Systematic uniform random
110 sampling involves random selection of the first sampling site, with subsequent sites dictated
111 by a pre-made sampling interval. This method is recommended to ensure representative and
112 unbiased sampling of the placenta^{29,30}. It is a simple method, allowing for even coverage of the
113 placenta and ensures that all sites can only be selected once²⁹. In practice, however, systematic
114 uniform random sampling has limitations. Firstly, its lack of bias may be compromised if the
115 pre-determined sampling interval coincides with a natural pattern existent in the placenta³⁰.
116 Secondly, placentae templates designed for systematic uniform random sampling assume all
117 placentas to be roughly circular in shape, with central umbilical cord insertion. This assumption
118 of a uniform shape and cord insertion however is incorrect. Although studies do show that
119 mean placental chorionic shape at term is round, deviations in placental shape are associated
120 with reduced placental efficiency³¹. In addition, the site of umbilical cord insertion appears to
121 be related to placental function, with a marginal cord insertion near the outer boundary of the
122 placenta being associated with a more asymmetric chorionic vessel structure³², which has been
123 associated with FGR, stillbirth and neonatal death³³.

124

125 While analysis of single sites may miss important histopathological and functional changes,
126 multiple site collection poses analytical challenges, and methods may still fail to identify

127 critical differences within placentas affected by pathology, such as FGR. Statistical modelling
128 allows for the exploration and integration of multiple data points from the same sample to
129 provide more accurate interpretation of functional consequences. Moreover, the use of
130 modelling to predict regional and disease state differences has high translational potential, for
131 example providing an explanation for why the pregnancy was compromised and which baby
132 may benefit the most from early health monitoring and/or postnatal intervention. With this
133 study we therefore, firstly sought to better understand if systematic uniform random sampling
134 methods could be optimised to the challenges that FGR placentas pose. Secondly, we sought
135 to characterise the degree of detailed histological and molecular heterogeneity between
136 multiple samples in healthy and FGR placentas and to examine potential links between
137 histological changes and the expression of genes involved in placental formation, transport,
138 and transcriptional regulation, and their relationships with fetal growth/pregnancy outcome.
139 Finally, in a proof of principle approach, we integrated these changes into a novel analysis
140 model to better delineate the significance of the placenta in health and disease.

141

142 **Results:**

143 **Patient characteristics**

144 We matched FGR cases and controls for maternal age, booking BMI, mode of delivery and
145 infant sex (Table 1) with expanded clinical data available (Supplementary Table 1).
146 Nonetheless, several significant differences in clinical characteristics were still observed. FGR
147 cases were more likely to be non-White and delivered infants with lower birth and placental
148 weights about a week earlier, although all delivered at term ($>36^{+6}$ weeks of gestation).

149

150 **Table 1: Patient characteristics.**

Characteristics	Control (N=9)	FGR (N=7)	P-value
Maternal age	34.44 \pm 1.84	32.00 \pm 1.16	0.339
Maternal ethnicity	8 white, 1 non-white	2 white, 5 non-white	0.035
Booking BMI (kg/m ²)	24.67 \pm 1.51	24.47 \pm 2.75	0.946
Mode of delivery	4 vaginal deliveries, 5 caesarean sections	2 vaginal deliveries, 5 caesarean sections,	0.620
Gestational age at delivery (weeks)	39.14 (39.07 – 39.79)	38.29 (37.29 – 39.00)	0.006
Infant sex	4F, 5M	2F, 5M	0.633
Infant birthweight (kg)	3.53 \pm 0.13	2.33 \pm 0.18	< 0.001

Placental weight (g)	478.9 ± 16.6	340.7 ± 31.0	0.001
----------------------	--------------	--------------	-------

151 Data are presented as mean ± SEM and were analysed by Student's t test or Mann-Whitney U
152 test. Categorical data were analysed by 2 X 2 contingency table with Fisher's Exact Test. BMI,
153 body mass index; F, female; M, male.

154

155 **Stereological analysis of placental morphology**

156 Comparing stereological findings by sampling site within the FGR or control groups showed
157 no significant differences between samples taken from the central and peripheral regions of the
158 placenta (Supplementary Table 2). Hence, we averaged the data of the central and peripheral
159 regions of each placenta to compare by pathology (Table 2). Taking into consideration a false
160 discovery rate of 5% for multiple testing, FGR placentas had significantly lower volume
161 densities of intermediate villi, syncytial knots and higher volume densities fibrosis and
162 capillaries. Once placental weight was accounted for, FGR cases showed decreased volumes
163 of intervillous spaces, intermediate villi, terminal villi, syncytial knots, trophoblast and stromal
164 components, and increased volume of fibrosis compared to control placentas. There were no
165 differences in any measure of barrier thickness, surface area, surface densities and diffusion
166 capacities between FGR and control placentas; except that FGR placentas had a decreased villi
167 surface area.

168

169 **Table 2: Morphological differences in the placenta by pathology**

	Control (N=9)	FGR (N=7)	P-value ([^]FDR)
Volume density (cm³/g)			
Intervillous space	0.37±0.01	0.36±0.02	0.447
Stem villi	0.06±0.01	0.06±0.01	0.895
Intermediate villi	0.12±0.01	0.08±0.01	0.008*
Terminal villi	0.42±0.02	0.4±0.03	0.474
Syncytial knots	0.02±0.00	0.01±0.00	0.002*
Fibrosis	0.01±0.01	0.1±0.02	0.001*
Trophoblast	0.32±0.01	0.34±0.03	0.583
Stromal	0.55±0.02	0.45±0.05	0.058
Capillary	0.13±0.01	0.21±0.03	0.016*
Volume (cm³)			
Intervillous space	179.73±9.45	119.44±10.77	0.001*
Stem villi	27.83±3.2	20.17±4.25	0.163
Intermediate villi	55.4±4.41	25.48±2.43	<0.001*
Terminal villi	200.73±10.54	135.3±16.23	0.003*
Syncytial knots	8.39±0.78	2.44±0.71	<0.001*
Fibrosis	5.88±3.24	37.02±7.43	0.001*
Trophoblast	153.5±6.83	114.7±13.69	0.017*
Stromal	263.09±15.46	153.23±21.66	0.001*
Capillary	62.3±5.04	72.78±13.76	0.445
Barrier thickness (µm)			
Arithmetic mean	2.83±0.08	2.85±0.18	0.912
Harmonic mean	2.14±0.07	2.24±0.14	0.500
Thickness uniformity index (a measure of thickness variability)	1.32±0.01	1.48±0.08	0.044
Surface density (cm²/cm³)			
Villi	610.45±23.85	630.28±44.68	0.683
Fetal capillary	298.26±19.81	401.92±48.29	0.048
Surface area (m²)			

Villi	11.68±2.88	10.59±1.55	0.009*
Fetal capillary	6.27±1.7	6.89±1.23	0.576
Theoretical diffusion capacity (cm²/min/kPa)	95.29±4.86	70.26±11.5	0.047
Specific diffusion capacity (cm²/min/kPa/g)	27.2±1.49	29.47±3.99	0.567


170 Data presented as mean ± SEM and analysed by t test with FDR (false discovery correction)
171 correction at 5%. * denotes significant findings that passed the 5% FDR.

172

173 **Placental expression of growth factors and nutrient transporters**

174 We also evaluated relative mRNA expression of selected growth factors and nutrient
175 transporters (Figure 1) that have been previously implicated in transcriptional control or with
176 compromised fetal growth in humans and animal models of FGR³⁴⁻³⁹. Placental *IGF2*, *SLC2A3*
177 and *SLC38A1* expression was significantly lower for FGR versus controls, regardless of
178 sampling location (Figures 1A, 2D and 2E). *VEGFA* expression was significantly lower in the
179 peripheral region as compared to the central region of FGR placentas, while no statistical
180 difference was identified in the central region between cases and controls (Figure 1B). Only
181 *SLC2A1* expression was significantly increased in FGR placenta as compared to controls,
182 independent of sampling location (Figure 1C). No differences in mRNA expression of and
183 *SLC38A2* were observed between FGR and control placentas or by sampling location (Figure
184 1F). In controls, placental *HNF1A* expression was higher in the peripheral region as compared
185 to the central region (Figure 1G), but no differences were identified for FGR.

186




188 **Figure 1: Relative mRNA expression of selected growth factors and nutrient transporters**
189 **in control and FGR placentas.** Expression of growth factors (*IGF2*, *VEGFA*), and
190 transporters (*SLC2A1*, *SLC2A3*, *SLC38A1*, *SLC38A2* and the transcription factor *HNF1A*),
191 were evaluated by qPCR. A total of 3 outliers were excluded; 1 control peripheral value for
192 *VEGFA*, and 1 control central value and 1 control peripheral value for *HNF1A*. Data are
193 presented with individual data points with mean \pm SEM and analysed with two-way ANOVA,
194 followed by Sidak's post hoc test for multiple comparisons. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$,
195 **** $p < 0.0001$.

196

197 **Associations between placental morphology and expression of functional genes**

198 We next evaluated relationships between placental morphology and the expression of growth
199 factor and nutrient transporter genes within the different sampling sites, and between control
200 and FGR groups using Pearson's r coefficient (Figure 2). In FGR placentas, several inverse
201 correlations were identified between expression of *IGF2*, *VEGFA*, *SLC38A1* and *SLC2A3* and
202 the volume of terminal villi, trophoblast, and capillary volume predominantly in the peripheral
203 region of FGR placentas. Inverse correlations with fibrosis volume were also observed for
204 expression *IGF2*, *VEGFA*, *SLC38A1* and *SLC2A3* in the central region of FGR placentas.
205 Additionally, the relative expression of *IGF2*, *VEGFA*, *SLC38A1* and *SLC2A3* genes was
206 inversely correlated with barrier thickness uniformity index and both maternal blood spaces
207 and fetal capillaries surface densities in the FGR placenta (central and peripheral sites),
208 although no significant correlations were detected for the control placenta. Moreover, the
209 expression of *IGF2*, *SLC38A1* and *SLC2A3* genes negatively correlated with both theoretical
210 and specific diffusion capacity in FGR, but not control placentas. In contrast, FGR expression
211 of *HNF1A* showed a positive correlation with specific diffusion capacity in the peripheral
212 region. Positive correlations between the expression of all genes measured and fibrosis and
213 stromal volumes were found for the peripheral region of control placentas, but not FGR
214 placentas. Positive relationships were also seen for expression of *VEGFA* and *HNF1A* with the
215 stem villi volume in central sites of control placentas.

216



217

218 **Figure 2. Correlations between stereological parameters and the relative expression of**
 219 **functional genes in the placenta.** Pearson's r coefficient was plotted and used to indicate
 220 strength of relationship between data (0: low, 1: high) and direction of correlation (+ sign:
 221 direct correlation and – sign: inverse correlation). Analysis was performed on each sampling
 222 site and experimental group (control and FGR) separately. Sample size was 36 for control and
 223 24 for FGR. *: $p < 0.05$, correlation is statistically significant.

224

225 Predictive modelling

226 To evaluate the information gained from different placental regions/sampling sites (only
 227 peripheral, only central, or both together) and data types (only stereological data, only qPCR
 228 data or both together), we considered all their possible combinations using predictive
 229 modelling (construction of classifiers that would make it possible to distinguish patients in the
 230 control group from patients with FGR). As predictive modelling was carried out using three
 231 machine learning (ML) methods; *xgbTree*, *glmnet* and *nnet*, this resulted in 27 models for
 232 consideration. The binary outcome of FGR was used as an outcome with chosen set of features
 233 (only stereological data, only qPCR data, both data types together) used as predictors. The
 234 predictive performance of each model was assessed using a leave-one-out cross-validation
 235 (LOOCV) scheme: the prediction was made for each patient (with all measurements) by
 236 excluding (withholding) it from the dataset, training the classifier on the remaining
 237 (independent) samples, and then generating predictions for the withheld samples using the
 238 trained model. Using predictions on the training subset (on each round of LOOCV procedures),
 239 the best threshold (corresponding to the best sum of sensitivity plus specificity) distinguishing

240 controls from FGR cases was found and a binary result was calculated for each withheld sample
241 (1 indicated FGR if the prediction was above the threshold, and 0 indicated control if it was
242 below the threshold). Through all rounds, LOOCV procedure binary results were collected for
243 withheld samples and performance was assessed using by these sets of predictions.
244 Performance was estimated using areas under the ROC curve (AUCs) in 2 ways: “AUC for all
245 samples” and “AUC for all patients”, as described in Methods. For each combination of
246 “placenta part + type of measurement + ML model” two such AUC values were obtained. Full
247 results of these analyses can be found in Table 3 (in addition, we provide a complete table of
248 errors for each patient in Supplementary Table 3). For a simplified visualization of these
249 results, we considered the distributions of results (AUCs) of different types of ML models on
250 different types of data obtained in different parts of the placenta for all patients and for all their
251 samples separately (Figure 3). This plot clearly shows that among the considered models, the
252 best are those based on measurements performed on the peripheral parts of the placenta and
253 using stereological and qPCR data together. As shown in Table 3, the best model was found to
254 be *nnet*, i.e., the model using simple artificial neural networks for a classification. This model
255 gave the best result for both “AUC for all samples” (0.979) and “AUC for all patients” (0.917).
256 By considering the stereological and qPCR data separately, the stereological data showed a
257 greater predictive power than the qPCR data (Figure 3, for all variants), which, may be due to
258 the clearly different interdependences of the stereological parameters of the control group and
259 the FGR group (the most significant interdependences are presented in Supplementary Figure
260 1). However, a combination of stereology and qPCR data works better than just stereology for
261 analyses on peripheral parts of the placenta (Figure 3). The results obtained on the central parts
262 of the placenta were lower than the results obtained on both parts of the placenta or only on the
263 peripheral (boxplots for the central parts are slightly lower than the other options). Moreover,
264 results using only peripheral parts were better than using a combination of both parts. Thus,
265 the best model would be that based on measures made on the peripheral parts of the placenta
266 using stereological and qPCR data together.

267


268

269 **Table 3: Predictive modelling results using different machine learning methods.**

Peripheral & Central									
	Stereology			qPCR			Stereology & qPCR		
	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet
AUC for all samples	0.899	0.913	0.927	0.705	0.733	0.719	0.875	0.92	0.948
AUC for all patients	0.611	0.861	0.917	0.639	0.528	0.528	0.694	0.861	0.917
Peripheral									
	Stereology			qPCR			Stereology & qPCR		
	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet
AUC for all samples	0.903	0.938	0.924	0.681	0.694	0.681	0.819	0.938	0.979
AUC for all patients	0.861	0.917	0.861	0.556	0.556	0.556	0.778	0.917	0.917
Central									
	Stereology			qPCR			Stereology & qPCR		
	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet
AUC for all samples	0.889	0.903	0.903	0.722	0.694	0.722	0.826	0.889	0.889
AUC for all patients	0.778	0.861	0.861	0.611	0.611	0.611	0.722	0.861	0.806

270 **Results for each combination of “placenta part + type of measurement + ML model”** The
 271 best version of the model is *nnet* model (highlighted in bold) on peripheral parts of placenta
 272 using stereological and qPCR data together. In this case, “AUC for all patients” = 0.917
 273 (corresponding to an error for just one patient-case in a sample of 15 patients: 9 controls and 6
 274 FGR), and “AUC for all samples” = 0.979 (corresponding to an error for only one

275 measurement, a FGR in a set of 15*4 samples: 9*4 control samples and 6*4 FGR samples). A
276 complete table of errors is given in Supplementary Table 3.
277



278
279 **Figure 3: Distributions of AUCs, i.e., the performance results of different types of models**
280 **on different types of data obtained on different parts of the placenta for all patients and**
281 **for all their measurements separately.**

282
283 **Discussion**

284 There was no significant variability in the morphological features of the placenta within and
285 between the peripheral and central sites of the placenta, regardless of whether they came from
286 a healthy or FGR pregnancy. In addition, the findings indicate that alterations in placental
287 morphology may be uniform across the placenta in late-onset FGR pregnancies without other
288 complications, such as pre-eclampsia, that can lead to more variable histological changes
289 across the placenta⁴⁰.

290
291 Despite established evidence that the placenta drives a number of the 'great obstetrical'
292 syndromes, which includes FGR, the relatively poor understanding of underlying placental
293 mechanisms makes interpretation of how they contribute to clinical presentations difficult⁴¹.
294 Heterogeneity within the placenta is thought to be responsible for some of the difficulties in
295 directly relating disease state to placental findings. Our results suggest that the systematic
296 sampling technique that we used was able to overcome potential morphological spatial
297 heterogeneity of the term placenta, whether from normal or late FGR pregnancies. Indeed,

298 peripheral versus central region comparisons revealed unique features in gene expression
299 correlations and predictive modelling results. These findings enable more clinical
300 interpretations to be made of the results and indicate that using of this sampling technique may
301 improve reproducibility between placental studies. This analysis suggests that at least a
302 peripheral and central sample should be taken when assessing placental function, particularly
303 in disease states.

304

305 Morphological differences between the control and FGR placenta are consistent with findings
306 of others⁴², and indicate villous mal-development, with fewer mature intermediate and terminal
307 villi and reduced villous surface area, as well as elevated fibrosis. The increased villous
308 capillary density and reduced syncytial knots in the studied FGR placentas are novel findings
309 and may reflect adaptive responses to hypoxic-reoxygenation events secondary to reduced
310 utero-placental and/or feto-placental flows in FGR pregnancies⁴³⁻⁴⁵. Moreover, these beneficial
311 changes in placental morphology may be the explanation for the FGR babies in our study
312 reaching near full term. Hence, morphological findings provide a clue to underlying placental
313 mechanisms that may be subject to change, with the resultant amelioration of disease and
314 improvement to fetal outcome, if they can be enacted *in utero*. There is already significant
315 interest in delivery of targeted agents to the uterine arteries to improve blood flow⁴⁶. Delivery
316 of agents to target specific areas of pathology and functional deficit within the placenta to
317 improve the clinical condition may also be a potential therapeutic option.

318

319 Our approach to combine morphological assessments with gene expression aimed to identify
320 some key aetiological pathways for the pathology seen. Expression of placental *IGF2*, *SLC2A3*
321 and *SLC38A1* was lower across the FGR placenta, correlating with volumes and other specific
322 placental features, suggesting a global role for these molecules in placental structure and
323 development in the presence of FGR. Indeed, *IGF2* is known to be important for the formation
324 of the placental exchange interface in humans, among other species^{38,39,47}, and is expressed at
325 lower levels in placentas showing FGR/small for gestational age in some^{48,49}, but not all
326 studies⁵⁰. Prior work has shown that a genetic deficiency of *SLC2A3* in mice leads to FGR³⁷
327 which supports our findings, but is in contrast to other work reporting an upregulation of its
328 encoded protein in the human placenta of late-onset FGR⁵¹. Of the system A amino acid
329 transporters expressed by the human placenta, *SLC38A1* is key for system A activity at term⁵².
330 Other work has also shown that placental system A activity is reduced in explants prepared
331 from term FGR placentas⁵³. *VEGFA* was significantly lower in the peripheral region of the

332 placenta in FGR and correlated to the following placental pathology (terminal villi, trophoblast
333 and capillary volume) that might suggest a causal association. This is consistent with other
334 work reporting lower placental *VEGFA* expression at term in late onset FGR^{54,55}, and the
335 involvement of angiogenic factors more generally in normal and pathological pregnancies⁵⁶.
336 Our findings also have relevance for emerging pre-clinical research in placenta-directed gene
337 therapy for FGR, including the utility of insulin-like growth factors and angiogenic
338 regulators⁵⁷. *HNF1A* was more highly expressed by the peripheral region compared with
339 central region in healthy, but not FGR placentas. Little is known about the function of *HNF1A*
340 in the placenta, although the human tissue atlas⁵⁸ indicates it is abundantly expressed by the
341 villous syncytiotrophoblast⁵⁹. Recent work has highlighted that *HNF1A* may regulate a large
342 number of genes in trophoblast cells⁶⁰ and mediate metabolic changes⁶¹, which could be
343 important for the placental support of fetal growth, more broadly.

344

345 Using a modelling approach in our discovery cohort, we demonstrated the potential of
346 predicting outcome (control or FGR) based on stereology and qPCR data. Stereology and qPCR
347 measurements taken from the peripheral part of the placenta, and analysed together, have the
348 highest predictive power. To avoid any possible overfitting of the models, we did not perform
349 any feature selection in advance for tuning of the algorithm hyperparameters. Despite this, we
350 were able to obtain predictions with very high accuracy, as, in fact, for the best model, only
351 one sample out of 60 (4 samples from peripheral placenta part for each of 15 patients)
352 considered was predicted incorrectly. Indeed, this subject was one that was most likely to be
353 misclassified in all of the tested models. Nevertheless, we found that the morphological data
354 clearly shows separation of features for control and FGR placentas and probably, this made it
355 possible to obtain high quality constructed models. For the present study, we used a very strict
356 LOOCV. Whilst modelling predictions were poor when qPCR data were used alone, adding
357 these data to the analysis of stereology data improved prediction, hence, confirming importance
358 of qPCR data and underlying link of these data with functional features. Whilst our modelling
359 approach shows potential, future work would benefit from utilising a larger dataset, with
360 extremes of pathology, to validate the model.

361

362 Overall, our data add to current understanding of placental function through comprehensive
363 sampling of healthy placentas and those affected by disease (FGR) with careful deep
364 histological analysis, integrated with expression of genes involved in key biological pathways
365 regulating placental function. Whilst, our modelling approach requires validation, with further

366 pathology analysed, it offers the promise of better diagnostic yield and novel insight into
367 biological pathways that affect FGR pregnancies.

368

369 **Material and methods:**

370 *Placental tissue collection and sampling*


371 Subjects were recruited from University College London Hospital NHS Foundation Trust,
372 London, UK with ethics approval from the South-Central Oxford A research ethics committee
373 (17/SC/0432). After written informed consent was obtained, term placental biopsies were
374 collected from subjects diagnosed with late-onset FGR (n=7, FGR detected after 32 weeks'
375 gestation and an estimated fetal weight and/or abdominal circumference below 3rd centile on
376 population-based charts used clinically⁶²), and from control subjects with appropriately grown
377 fetuses (n=9 birthweight >10th centile and <90th centile). Data on maternal pre-existing
378 conditions, previous obstetric history, ultrasound examination, and pregnancy complications
379 were collected at the time of recruitment.

380

381 Placentas were weighed and sampled within 30 minutes of delivery. Sampling sites were
382 chosen to be representative of four central and four peripheral regions always relative to cord
383 insertion (Figure 4A). In marginal cord insertions, the placenta was orientated with the cord
384 anterior. Sampling then took place relative to the cord insertion as in other cases. This meant
385 there was one site that had less tissue to sample from initially, in non-central cord insertions,
386 but that ultimately the same amount of tissue was sampled, and that tissue selection was directly
387 related to the cord in the same way as all other samples. For each placenta, 8 tissue biopsies
388 (with maternal tissue and fetal chorionic plate removed) were snap frozen using liquid nitrogen
389 or dry ice and stored at -80°C. Neighboring sampling sites were then immersion-fixed in 4%
390 paraformaldehyde.

391

392



393

394

395 **Figure 4. Diagram showing sampling of placenta (A) and main parameters measured in**

396 **histological sections of placenta (B-D).** (A) Dotted lines indicate where the placenta should

397 be cut with a sterile histology knife. Red boxes with single letters indicate inner sections.

398 Yellow boxes with double letters indicate outer sections. Green rectangles represent samples

399 taken for RNA sampling. The central blue circle represents the umbilical cord (cut). (B-D)

400 Representative histological sections of term human placenta. Stereological analysis was

401 performed by identifying the intervillous space (IVS), stem villi (SV), intermediate villi

402 (INTV), terminal villi (TV), fibrosis (FIB), syncytial knots (*); and under higher magnification

403 of terminal villi, the trophoblast cell layer (#), fetal capillaries (+) and stromal cells (^). The

404 scale bar denotes 50 μm.

405

406 **RNA extraction, cDNA synthesis and qPCR**

407 Total RNA was extracted from n=9 control and n=6 FGR frozen placental tissues (n=1 FGR
408 sample was not taken due to >30 minute delay in freezing this sample) using the RNeasy
409 Fibrous Tissue Mini Kit (Qiagen, Hilden, Germany) following the manufacturer's protocol.
410 Briefly, approximately 2mg of tissue was added to 300µl of lysis buffer and homogenized
411 using a bead-based technique. Following treatment with proteinase K and addition of 100%
412 ethanol, the homogenate was transferred to the spin columns, washed with supplied buffers
413 and centrifuged to remove contaminants. Purified RNA was then eluted into RNase-free water.
414 Quality and concentration of extracted RNA were determined by Nanodrop (Thermo Fisher
415 Scientific, Waltham, CA, USA).

416
417 Complementary DNA (cDNA) was synthesized using the Applied Biosystems High-Capacity
418 cDNA Reverse Transcription Kit (Thermo Fisher Scientific) according to manufacturer's
419 instructions on a thermal cycler. Real-time PCR was performed in duplicate using TaqMan™
420 Universal Master Mix II, with UNG (Thermo Fisher Scientific) and inventoried TaqMan®
421 gene expression assay probes with either VIC and FAM fluorophores for 5 housekeeping genes
422 (*18SrRNA*, *B2M*, *GAPDH*, *GUSB* and *YWHAZ*) and 8 genes of interest (*HNF1A*, *IGF2*,
423 *SLC2A1*, *SLC2A3*, *SLC38A1*, *SLC38A2*, *SLC38A4* and *VEGFA*) (Table 4). Only stable
424 housekeeping genes (*18S rRNA*, *B2M*, *GADPH* and *YWHAZ*) that showed no statistically
425 significant differences between cases and controls were included in the housekeeper geomean
426 calculation for normalising gene expression across samples. The relative expression of genes
427 of interest was then calculated using the $2^{-\Delta\Delta C_t}$ method.

428

429 **Table 4 Probes used for real-time PCR**

Analysed genes	Gene symbol	Probe ID	Fluorophore
Housekeeping genes	<i>18S rRNA</i>	Hs99999901_s1	VIC
	<i>B2M</i>	Hs00187842_m1	VIC
	<i>GAPDH</i>	Hs02786624_g1	VIC
	<i>GUSB</i>	Hs00939627_m1	VIC
	<i>YWHAZ</i>	Hs01122445_g1	VIC
Genes of interest	<i>HNF1A</i>	Hs00167041_m1	VIC
	<i>IGF2</i>	Hs04188276_m1	FAM
	<i>SLC2A1</i>	Hs00892681_m1	FAM

	<i>SLC2A3</i>	Hs00359840_m1	FAM
	<i>SLC38A1</i>	Hs01562175_m1	FAM
	<i>SLC38A2</i>	Hs01089954_m1	VIC
	<i>SLC38A4</i>	Hs00394339_m1	FAM
	<i>VEGFA</i>	Hs00900055_m1	FAM

430

431 ***Histological preparation***

432 Following paraformaldehyde fixation, biopsies of 8 sites from each control (n=9) and FGR
433 (n=7) placenta were embedded in paraffin using routine histological techniques and sectioned
434 at 7 μ m thickness. Sections were rehydrated using xylene and ethanol gradients, stained with
435 haematoxylin and eosin, dehydrated with ethanol gradients and xylene, then mounted with
436 DPX. Slides were then scanned using a Nanozoomer digital slide scanner (Hamamatsu
437 Photonics, Shizuoka Prefecture, Japan).

438

439 ***Placental stereology***

440 Placentas were analysed blinded to the diagnosis of FGR. To perform stereological analysis in
441 a manner similar to that performed previously⁶³; transparent lattices with test points, test lines
442 or test arcs were superimposed onto scanned images viewed under different magnification on
443 the NDP.view2 software (Hamamatsu Photonics). Volume densities of the intervillous space,
444 stem villi, intermediate villi, terminal villi, syncytial knots, and fibrosis (Figure 4B-C) were
445 estimated by point counting and a lattice of equally spaced test points arranged 4 by 4 under
446 10X magnification in at least 13 fields of view for a minimum of 200 measurements per section.
447 Volume densities of the trophoblast, stroma, and fetal capillaries (Figure 4D) within villi were
448 estimated under a similar lattice under 40X magnification in 20 fields of view per sample.
449 Absolute placental volumes were estimated by multiplying volume densities with placental
450 weight (g). Arithmetic barrier thickness was assessed under 100X magnification in 20 fields of
451 view per sample and a superimposed lattice with equally spaced straight test lines, which at
452 times, intersected fetal capillary and villous trophoblast involved in exchange. The 'measure'
453 tool within the software was then used to determine the shortest distance between a fetal
454 capillary and the maternal blood space, where there was an intersection. Mean harmonic barrier
455 thickness was calculated using the inverse of mean reciprocal of each raw arithmetic barrier
456 thickness measurement. Thickness uniformity index, as a measure of the variability in
457 thickness across the villous membrane, was obtained from the ratio of the mean arithmetic

458 barrier thickness to the mean harmonic barrier thickness. Surface densities were approximated
459 by counting chance intersections of fetal capillaries and villous trophoblast involved in
460 exchange with superimposed test arc lines under 40X magnification. To derive surface areas,
461 surface densities were multiplied by placental villous volume. The theoretical diffusion
462 capacity was calculated using the total surface area for exchange (averaged surface area of fetal
463 capillaries and villi) divided by the mean harmonic barrier thickness and multiplied by Krogh's
464 constant for oxygen diffusion. Specific diffusion capacity was then calculated by dividing the
465 theoretical diffusion capacity by the infant birthweight.

466

467 ***Predictive modelling***

468 To evaluate the informativity of different placental sampling locations (only peripheral, only
469 central or both regions together) and different data types (only stereological data, only PCR
470 data or both types together), we studied all their possible combinations with analysis performed
471 in R (version 4.0.2). To analyse several well-established multi-dimensional methods of data
472 analysis, the machine learning models (*xgbTree*, *glmnet* and *nnet*) were implemented using
473 *caret* package (version 6.0.90). All 27 models were trained with default set of hyperparameters,
474 cross-validated on 5 folds (for a better selection of internal algorithm parameters), with seed
475 parameter set to 123. The performance of models was assessed with receiver operating
476 characteristic (ROC) curves using area under the curve (AUC) with 95% confidence intervals
477 (*pROC* package, version 1.18.0). Results of AUCs were presented in two ways:

- 478 - *All sample's AUC* - Calculating AUC considering all samples as independent;
- 479 - *All patient's AUC* - Calculating AUC on patient's result's only (if all samples belonging
480 to one patient were correctly predicted, then we assumed that a prediction for this
481 patient was correct, if the prediction was wrong in at least one sample of the sample's
482 patient, then it was set as wrong for this patient).

483 For illustration of interdependencies of features, which are presented in Supplementary Figure
484 1, we selected the best pairs that showed significant differences between FGR and control
485 groups using ANOVA test after applying FDR (false discovery rate) adjustment to test's p-
486 values (*stats* package, Version 4.0.2).

487

488 ***Statistical analyses***

489 Normality of data was assessed by D'Agostino-Pearson normality test. ROUT testing for
490 outliers was used to identify any outliers, which were then excluded from the analysis. For
491 comparisons between 2 groups, Student's t tests and Mann-Whitney U tests were performed

492 for parametric and non-parametric continuous data, respectively. Categorical data between
493 FGR and controls were analysed by a 2 X 2 contingency table with Fisher's Exact Test. Two-
494 way ANOVAs followed by Sidak post hoc test for multiple comparisons were used to analyse
495 mRNA expression data by pathology and sampling location. Graphpad Prism 6.01 (Graphpad
496 Software Inc., La Jolla, CA, USA) was used for statistical analyses. A p-value of <0.05 was
497 considered statistically significant for clinical characteristics and mRNA expression analysis.
498 To account for multiple testing in histological analyses, a false discovery rate correction at 5%
499 was applied to determine statistical significance.

500

501 **Acknowledgements**

502 ANSP received funding for this work via an Academy of Medical Sciences Springboard Grant,
503 Dorothy Hodgkin Research Fellowship (DH130036/RG74249), MRC New Investigator Grant
504 (MR/R022690/1/RG93186) and Lister Institute of Preventative Medicine Research Prize
505 (RG93692). TN and AZ are supported by a Medical Research Council grant (MR/R02524X/1).
506 HEJY was supported by an A*STAR International Fellowship from the Agency for Science,
507 Technology and Research. KM was supported by UCLH Charity and the Mitchell Charitable
508 Trust. SLH received funding for this work via an Academy of Medical Sciences Clinical
509 Lecturer Starter Grant and the UCLH EGA Obstetric Charity.

510

511 **Author contributions**

512 HEJY, KM, SLH and ANSP designed the study. HEJY, KM, MABY, ESP collected and/or
513 performed experiments. HEJY, KM, ESP and TN analysed and graphed the data. TN and AZ
514 provided predictive modelling analysis. HEJY, KM, TN, AZ, ALD, SLH and ANSP interpreted
515 the data. HEJY, KM, SLH and ANSP wrote the paper. All authors performed final editing
516 checks and approved the final manuscript.

517

518

519 **References**

520

- 521 1 Napso, T., Yong, H. E., Lopez-Tello, J. & Sferruzzi-Perri, A. N. The role of placental
522 hormones in mediating maternal adaptations to support pregnancy and lactation.
523 *Front Physiology* **9**:1091, doi:10.3389/fphys.2018.01091 (2018).
- 524 2 Burton, G. J., Fowden, A. L. & Thornburg, K. L. Placental Origins of Chronic Disease.
525 *Physiological reviews* **96**, 1509-1565, doi:10.1152/physrev.00029.2015 (2016).
- 526 3 Byrne, M. *et al.* Structure-function relationships in the feto-placental circulation
527 from in silico interpretation of micro-CT vascular structures. *J Theor Biol* **517**,
528 110630, doi:10.1016/j.jtbi.2021.110630 (2021).
- 529 4 Aughwane, R. *et al.* Micro-CT and histological investigation of the spatial pattern of
530 feto-placental vascular density. *Placenta* **88**, 36-43,
531 doi:10.1016/j.placenta.2019.09.014 (2019).
- 532 5 World Health, O. *Every newborn: an action plan to end preventable deaths*. 55 p.
533 (World Health Organization, 2014).
- 534 6 Lawn, J. E. *et al.* Every Newborn: progress, priorities, and potential beyond survival.
535 *Lancet* **384**, 189-205, doi:10.1016/S0140-6736(14)60496-7 (2014).
- 536 7 Sharma, D., Shastri, S. & Sharma, P. Intrauterine Growth Restriction: Antenatal and
537 Postnatal Aspects. *Clin Med Insights Pediatr* **10**, 67-83, doi:10.4137/CMPed.S40070
538 (2016).
- 539 8 Gordijn, S. J. *et al.* Consensus definition of fetal growth restriction: a Delphi
540 procedure. *Ultrasound Obstet Gynecol* **48**, 333-339, doi:10.1002/uog.15884 (2016).
- 541 9 Van den Berg, B. J. & Yerushalmy, J. The relationship of the rate of intrauterine
542 growth of infants of low birth weight to mortality, morbidity, and congenital
543 anomalies. *J Pediatr* **69**, 531-545, doi:10.1016/s0022-3476(66)80038-0 (1966).
- 544 10 Bianchi, M. E. & Restrepo, J. M. Low Birthweight as a Risk Factor for Non-
545 communicable Diseases in Adults. *Front Med (Lausanne)* **8**, 793990,
546 doi:10.3389/fmed.2021.793990 (2021).
- 547 11 Caradeux, J., Martinez-Portilla, R. J., Basuki, T. R., Kiserud, T. & Figueras, F. Risk of
548 fetal death in growth-restricted fetuses with umbilical and/or ductus venosus absent
549 or reversed end-diastolic velocities before 34 weeks of gestation: a systematic
550 review and meta-analysis. *Am J Obstet Gynecol* **218**, S774-S782 e721,
551 doi:10.1016/j.ajog.2017.11.566 (2018).
- 552 12 Ishihara, N. *et al.* Increased apoptosis in the syncytiotrophoblast in human term
553 placentas complicated by either preeclampsia or intrauterine growth retardation.
554 *Am J Obstet Gynecol* **186**, 158-166, doi:10.1067/mob.2002.119176 (2002).
- 555 13 Mayhew, T. M., Wijesekara, J., Baker, P. N. & Ong, S. S. Morphometric evidence that
556 villous development and fetoplacental angiogenesis are compromised by
557 intrauterine growth restriction but not by pre-eclampsia. *Placenta* **25**, 829-833,
558 doi:10.1016/j.placenta.2004.04.011 (2004).
- 559 14 Macara, L. *et al.* Structural analysis of placental terminal villi from growth-restricted
560 pregnancies with abnormal umbilical artery Doppler waveforms. *Placenta* **17**, 37-48,
561 doi:10.1016/s0143-4004(05)80642-3 (1996).
- 562 15 Teasdale, F. & Jean-Jacques, G. Intrauterine growth retardation: morphometry of the
563 microvillous membrane of the human placenta. *Placenta* **9**, 47-55 (1988).

- 564 16 Burton, G. J. & Fowden, A. L. The placenta: a multifaceted, transient organ. *Philos*
565 *Trans R Soc Lond B Biol Sci* **370**, 20140066, doi:10.1098/rstb.2014.0066 (2015).
- 566 17 Chavatte-Palmer, P. & Tarrade, A. Placentation in different mammalian species. *Ann*
567 *Endocrinol (Paris)* **77**, 67-74, doi:10.1016/j.ando.2016.04.006 (2016).
- 568 18 Pere, M. C. Materno-foetal exchanges and utilisation of nutrients by the foetus:
569 comparison between species. *Reprod Nutr Dev* **43**, 1-15, doi:10.1051/rnd:2003002
570 (2003).
- 571 19 Crawford, M. A., Hassam, A. G. & Williams, G. Essential fatty acids and fetal brain
572 growth. *Lancet* **1**, 452-453, doi:10.1016/s0140-6736(76)91476-8 (1976).
- 573 20 Gresham, E. L., Simons, P. S. & Battaglia, F. C. Maternal-fetal urea concentration
574 difference in man: metabolic significance. *J Pediatr* **79**, 809-811, doi:10.1016/s0022-
575 3476(71)80396-7 (1971).
- 576 21 Sferruzzi-Perri, A. N. *et al.* Placental-specific Igf2 deficiency alters developmental
577 adaptations to undernutrition in mice. *Endocrinology* **152**, 3202-3212,
578 doi:10.1210/en.2011-0240 (2011).
- 579 22 Sferruzzi-Perri, A. N. *et al.* An obesogenic diet during mouse pregnancy modifies
580 maternal nutrient partitioning and the fetal growth trajectory. *Faseb J* **27**, 3928-
581 3937, doi:10.1096/fj.13-234823 (2013).
- 582 23 Vaughan, O. R., Sferruzzi-Perri, A. N. & Fowden, A. L. Maternal corticosterone
583 regulates nutrient allocation to fetal growth in mice. *The Journal of physiology* **590**,
584 5529-5540 (2012).
- 585 24 Higgins, J. S., Vaughan, O. R., de Liger, E. F., Fowden, A. L. & Sferruzzi-Perri, A. N.
586 Placental phenotype and resource allocation to fetal growth are modified by the
587 timing and degree of hypoxia during mouse pregnancy. *J Physiol* **594**, 1341-1356,
588 doi:10.1113/JP271057 (2015).
- 589 25 Napso, T., Hung, Y. P., Davidge, S. T., Care, A. S. & Sferruzzi-Perri, A. N. Advanced
590 maternal age compromises fetal growth and induces sex-specific changes in
591 placental phenotype in rats. *Sci Rep* **9**, 16916, doi:10.1038/s41598-019-53199-x
592 (2019).
- 593 26 Lewis, R. M. & Sferruzzi-Perri, A. N. in *Developmental Origins of Health and Disease*
594 (eds L. Poston, K. M. Godfrey, M. A. Hanson, & P. Gluckman) (Cambridge University
595 Press).
- 596 27 Audette, M. C., McLaughlin, K. & Kingdom, J. C. Second Trimester Placental Growth
597 Factor Levels and Placental Histopathology in Low-Risk Nulliparous Pregnancies. *J*
598 *Obstet Gynaecol Can* **43**, 1145-1152 e1141, doi:10.1016/j.jogc.2021.01.018 (2021).
- 599 28 Burton, G. J. *et al.* Optimising sample collection for placental research. *Placenta* **35**,
600 9-22, doi:10.1016/j.placenta.2013.11.005 (2014).
- 601 29 Mayhew, T. M. Taking tissue samples from the placenta: an illustration of principles
602 and strategies. *Placenta* **29**, 1-14, doi:10.1016/j.placenta.2007.05.010 (2008).
- 603 30 Mayhew, T. M. Morphomics: An integral part of systems biology of the human
604 placenta. *Placenta* **36**, 329-340, doi:10.1016/j.placenta.2015.01.001 (2015).
- 605 31 Salafia, C. M. *et al.* Placental surface shape, function, and effects of maternal and
606 fetal vascular pathology. *Placenta* **31**, 958-962, doi:10.1016/j.placenta.2010.09.005
607 (2010).
- 608 32 Gordon, Z. *et al.* Anthropometry of fetal vasculature in the chorionic plate. *J Anat*
609 **211**, 698-706, doi:10.1111/j.1469-7580.2007.00819.x (2007).

- 610 33 Heifetz, S. A. The umbilical cord: obstetrically important lesions. *Clin Obstet Gynecol*
611 **39**, 571-587, doi:10.1097/00003081-199609000-00007 (1996).
- 612 34 Sferruzzi-Perri, A. N. & Camm, E. J. The programming power of the placenta.
613 *Frontiers in Physiology* **7:33**, doi:10.3389/fphys.2016.00033 (2016).
- 614 35 Vaughan, O. R. *et al.* Placenta-specific Slc38a2/SNAT2 knockdown causes fetal
615 growth restriction in mice. *Clin Sci (Lond)* **135**, 2049-2066, doi:10.1042/CS20210575
616 (2021).
- 617 36 Luscher, B. P. *et al.* Placental glucose transporter (GLUT)-1 is down-regulated in
618 preeclampsia. *Placenta* **55**, 94-99, doi:10.1016/j.placenta.2017.04.023 (2017).
- 619 37 Ganguly, A. *et al.* Glucose transporter isoform-3 mutations cause early pregnancy
620 loss and fetal growth restriction. *American journal of physiology* **292**, E1241-1255
621 (2007).
- 622 38 Sferruzzi-Perri, A. N., Owens, J. A., Pringle, K. G. & Roberts, C. T. The neglected role
623 of insulin-like growth factors in the maternal circulation regulating fetal growth. *The*
624 *Journal of physiology* **589**, 7-20 (2010).
- 625 39 Sferruzzi-Perri, A. N., Sandovici, I., Constancia, M. & Fowden, A. L. Placental
626 phenotype and the insulin-like growth factors: resource allocation to fetal growth.
627 *The Journal of physiology* **595**, 5057-5093 (2017).
- 628 40 Mifsud, W. & Sebire, N. J. Placental pathology in early-onset and late-onset fetal
629 growth restriction. *Fetal Diagn Ther* **36**, 117-128, doi:10.1159/000359969 (2014).
- 630 41 Brosens, I., Pijnenborg, R., Vercruyssen, L. & Romero, R. The "Great Obstetrical
631 Syndromes" are associated with disorders of deep placentation. *Am J Obstet Gynecol*
632 **204**, 193-201, doi:10.1016/j.ajog.2010.08.009 (2011).
- 633 42 Burton, G. J. & Jauniaux, E. Pathophysiology of placental-derived fetal growth
634 restriction. *Am J Obstet Gynecol* **218**, S745-S761, doi:10.1016/j.ajog.2017.11.577
635 (2018).
- 636 43 Kovo, M. *et al.* Placental vascular lesion differences in pregnancy-induced
637 hypertension and normotensive fetal growth restriction. *Am J Obstet Gynecol* **202**,
638 561 e561-565, doi:10.1016/j.ajog.2010.01.012 (2010).
- 639 44 Colson, A., Sonveaux, P., Debieve, F. & Sferruzzi-Perri, A. N. Adaptations of the
640 human placenta to hypoxia: opportunities for interventions in fetal growth
641 restriction. *Hum Reprod Update*, doi:10.1093/humupd/dmaa053 (2020).
- 642 45 Cindrova-Davies, T. & Sferruzzi-Perri, A. N. Human placental development and
643 function. *Seminars in Cell and Developmental Biology* **In press** (2022).
- 644 46 David, A. L. *et al.* Local delivery of VEGF adenovirus to the uterine artery increases
645 vasorelaxation and uterine blood flow in the pregnant sheep. *Gene Ther* **15**, 1344-
646 1350, doi:10.1038/gt.2008.102 (2008).
- 647 47 Sferruzzi-Perri, A. N. Regulating needs: Exploring the role of insulin-like growth
648 factor-2 signalling in materno-fetal resource allocation. *Placenta Suppl* **1**, S16-S22,
649 doi:10.1016/j.placenta.2018.01.005 (2018).
- 650 48 Guo, L. *et al.* Altered gene expression and methylation of the human chromosome
651 11 imprinted region in small for gestational age (SGA) placentae. *Dev Biol* **320**, 79-91,
652 doi:10.1016/j.ydbio.2008.04.025 (2008).
- 653 49 Yamaguchi, Y. *et al.* Placenta-specific epimutation at H19-DMR among common
654 pregnancy complications: its frequency and effect on the expression patterns of H19
655 and IGF2. *Clin Epigenetics* **11**, 113, doi:10.1186/s13148-019-0712-3 (2019).

- 656 50 Antonazzo, P. *et al.* Placental IGF2 Expression in Normal and Intrauterine Growth
657 Restricted (IUGR) Pregnancies. *Placenta* **29**, 99-101 (2008).
- 658 51 Janzen, C. *et al.* Placental glucose transporter 3 (GLUT3) is up-regulated in human
659 pregnancies complicated by late-onset intrauterine growth restriction. *Placenta* **34**,
660 1072-1078, doi:10.1016/j.placenta.2013.08.010 (2013).
- 661 52 Desforges, M., Greenwood, S. L., Glazier, J. D., Westwood, M. & Sibley, C. P. The
662 contribution of SNAT1 to system A amino acid transporter activity in human
663 placental trophoblast. *Biochem Biophys Res Commun* **398**, 130-134,
664 doi:10.1016/j.bbrc.2010.06.051 (2010).
- 665 53 Shibata, E. *et al.* Placental System A Amino Acid Transport is Reduced in Pregnancies
666 With Small For Gestational Age (SGA) Infants but Not in Preeclampsia with SGA
667 Infants. *Placenta* **29**, 879-882 (2008).
- 668 54 Lash, G. *et al.* Abnormal fetal growth is not associated with altered chorionic villous
669 expression of vascular endothelial growth factor mRNA. *Mol Hum Reprod* **7**, 1093-
670 1098, doi:10.1093/molehr/7.11.1093 (2001).
- 671 55 Lyall, F., Young, A., Boswell, F., Kingdom, J. C. & Greer, I. A. Placental expression of
672 vascular endothelial growth factor in placentae from pregnancies complicated by
673 pre-eclampsia and intrauterine growth restriction does not support placental
674 hypoxia at delivery. *Placenta* **18**, 269-276, doi:10.1016/s0143-4004(97)80061-6
675 (1997).
- 676 56 Andraweera, P. H., Dekker, G. A. & Roberts, C. T. The vascular endothelial growth
677 factor family in adverse pregnancy outcomes. *Hum Reprod Update* **18**, 436-457,
678 doi:10.1093/humupd/dms011 (2012).
- 679 57 Krishnan, T. & David, A. L. Placenta-directed gene therapy for fetal growth
680 restriction. *Semin Fetal Neonatal Med* **22**, 415-422, doi:10.1016/j.siny.2017.04.005
681 (2017).
- 682 58 Uhlen, M. *et al.* Proteomics. Tissue-based map of the human proteome. *Science* **347**,
683 1260419, doi:10.1126/science.1260419 (2015).
- 684 59 Human Protein Atlas Team. *Human Protein Atlas - HNF1A in the placenta*,
685 <<https://www.proteinatlas.org/ENSG00000135100-HNF1A/tissue/placenta>> (
686 60 Ducat, A. *et al.* Low-dose aspirin protective effects are correlated with deregulation
687 of HNF factor expression in the preeclamptic placentas from mice and humans. *Cell*
688 *Death Discov* **5**, 94, doi:10.1038/s41420-019-0170-x (2019).
- 689 61 Rout, M. & Lulu, S. S. Molecular and disease association of gestational diabetes
690 mellitus affected mother and placental datasets reveal a strong link between insulin
691 growth factor (IGF) genes in amino acid transport pathway: A network biology
692 approach. *J Cell Biochem*, doi:10.1002/jcb.27418 (2018).
- 693 62 Brenner, W. E., Edelman, D. A. & Hendricks, C. H. A standard of fetal growth for the
694 United States of America. *Am J Obstet Gynecol* **126**, 555-564, doi:10.1016/0002-
695 9378(76)90748-1 (1976).
- 696 63 Mayhew, T. M. Stereology and the placenta: where's the point? -- a review. *Placenta*
697 **27 Suppl A**, S17-25, doi:10.1016/j.placenta.2005.11.006 (2006).

698

699

700

701 SUPPLEMENTARY INFORMATION

702 Supplementary Table 1: Full phenotype clinical data.

ID	Status	Medical history	Pregnancy complications	Maternal age quartile (years)	Ethnicity	Maternal booking BMI	Delivery mode	Gestation	Birthweight (g)	Infant sex	Placenta weight (g)	Placenta/BW ratio (%)	Analysis comments
Control 1	Control			31-35	Asian	34	Vaginal delivery	39+6	3200	Male	442	13.8	
Control 2	Control			36-40	White	21	cat4 CS	39+1	3690	Female	516	14.0	
Control 3	Control			21-25	White	20	Vaginal delivery	39+0	3800	Female	534	14.1	
Control 4	Control			31-35	White	23	cat3 CS	41+1	3970	Male	509	12.8	
Control 5	Control			41-45	White	27	cat4 CS	39+1	3960	Female	481	12.1	
Control 6	Control			36-40	White	24	cat4 CS	39+1	2893	Female	413	14.3	
Control 7	Control			36-40	White	23	Vaginal delivery	39+0	3618	Male	491	13.6	
Control 8	Control			36-40	White	23	cat4 CS	39+1	3140	Male	398	12.7	
Control 9	Control			31-35	White	28	Vaginal delivery	39+5	3510	Male	526	15.0	
FGR 1	Late FGR			31-35	White	23	cat3 CS	37+0	1410	Male	160	11.3	

FGR 2	Late FGR	Hypothyroid		31-35	White	22	Vaginal delivery	37+5	2510	Female	346	13.8	
FGR 3	Late FGR	Migraines		31-35	Chinese	22	cat2 CS	37+2	2560	Male	380	14.8	
FGR 4	Late FGR		Low platelets	26-30	Afro Caribbean	22	cat2 CS	38+2	1985	Male	380	19.1	
FGR 5	Late FGR			31-35	Chinese	20	Vaginal delivery	39+4	2720	Female	360	13.2	
FGR 6	Late FGR		Gestational diabetes	31-35	Asian	38	cat1 CS	38+4	2396	Male	355	14.8	
FGR 7	Late FGR			36-40	Afro Caribbean	28	cat3 CS	39+0	2750	Male	404	14.7	Not run for qPCR

703

704 CS = caesarean section. Cat1 = Immediate threat to the life of the woman or fetus, Cat2 = Maternal or fetal compromise which is not immediately
705 life-threatening, Cat3 = No maternal or fetal compromise but needs early birth, Cat4 = Birth timed to suit woman or healthcare provider. (NICE
706 guideline 192: Caesarean birth, published 31 March 2021).

707

Supplementary Table 2: Morphological differences in the placenta by sampling location.

	Control (N=9)			FGR (N=7)		
	Central	Peripheral	P-value	Central	Peripheral	P-value
Volume density (cm³/g)						
Intervillous space	0.39±0.02	0.36±0.01	0.130	0.36±0.02	0.35±0.02	0.577
Stem villi	0.06±0.01	0.06±0.01	0.902	0.06±0.02	0.05±0.01	0.364
Intermediate villi	0.1±0.01	0.13±0.01	0.105	0.08±0.01	0.08±0.01	0.720
Terminal villi	0.42±0.02	0.42±0.02	0.941	0.41±0.03	0.38±0.03	0.526
Syncytial knots	0.02±0.00	0.02±0.00	0.633	0.01±0.00	0.01±0.00	0.591
Fibrosis	0.01±0.00	0.02±0.01	0.443	0.07±0.02	0.13±0.03	0.091
Trophoblast	0.33±0.02	0.31±0.01	0.492	0.34±0.02	0.33±0.04	0.818
Stromal	0.53±0.03	0.57±0.02	0.239	0.45±0.04	0.46±0.06	0.865
Capillary	0.14±0.01	0.12±0.01	0.139	0.21±0.03	0.21±0.03	0.963
Volume (cm³)						
Intervillous space	187.75±10.19	171.7±9.96	0.277	121.96±11.52	116.92±10.14	0.748
Stem villi	27.82±5.18	27.85±2.89	0.100	23.24±6.3	17.1±2.58	0.385
Intermediate villi	49.91±4.81	60.89±5.94	0.170	24.77±2.83	26.19±2.23	0.700
Terminal villi	199.23±8.7	202.24±13.7	0.855	141.08±17.48	129.51±15.51	0.630
Syncytial knots	8.89±0.9	7.89±1.12	0.495	2.24±0.66	2.63±0.82	0.720
Fibrosis	3.9±1.93	7.87±4.69	0.446	26.28±6.89	47.77±9.57	0.094
Trophoblast	156.49±6.76	150.51±8.25	0.583	117.28±13.22	112.13±15.07	0.802

Stromal	254.68±18.75	271.49±12.97	0.472	150.39±19.02	156.07±25.00	0.860
Capillary	67.72±5.88	56.89±5.04	0.181	73.05±14.18	72.51±13.58	0.979
Barrier thickness (µm)						
Arithmetic mean	2.84±0.08	2.82±0.10	0.885	2.84±0.19	2.86±0.18	0.940
Harmonic mean	2.14±0.07	2.15±0.07	0.918	2.24±0.15	2.24±0.14	0.987
Thickness uniformity index	1.33±0.02	1.31±0.02	0.508	1.47±0.08	1.48±0.08	0.936
Surface density (cm²/cm³)						
Villi	613.67±27.94	607.22±24.07	0.863	634.49±43.19	626.07±47.42	0.898
Fetal capillary	318.63±27.71	277.88±13.62	0.206	406.06±47.11	397.78±51.52	0.906
Surface area (m²)						
Villi	15.32±0.97	15.99±0.92	0.622	10.87±1.63	10.3±1.51	0.801
Fetal capillary	7.89±0.75	7.32±0.44	0.519	7.11±1.31	6.67±1.2	0.807
Theoretical diffusion capacity (cm²/min/kPa)	94.95±5.96	95.64±4.31	0.926	71.63±11.95	68.89±11.61	0.872
Specific diffusion capacity (cm²/min/kPa/g)	27.15±1.86	27.24±1.23	0.968	30.24±4.58	28.7±3.71	0.798

Supplementary Table 3: Summary tables of errors in all 27 models for each patient.

ONLY PERIPHERAL										
id	score	STEREOLOGY & PCR			PCR			STEREOLOGY		
		xgbTree	glmnet	nnet	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet
Control 1	0	0of4	0of4	0of4	1of4	1of4	1of4	0of4	0of4	0of4
Control 2	0	1of4	0of4	0of4	0of4	0of4	0of4	1of4	0of4	0of4
Control 3	0	0of4	0of4	0of4	0of4	1of4	1of4	0of4	0of4	0of4
Control 4	0	0of4	0of4	0of4	4of4	3of4	3of4	0of4	0of4	0of4
Control 5	0	0of4	0of4	0of4	2of4	0of4	0of4	0of4	0of4	0of4
Control 6	0	0of4	0of4	0of4	3of4	3of4	4of4	0of4	0of4	0of4
Control 7	0	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4
Control 8	0	0of4	0of4	0of4	1of4	2of4	2of4	0of4	0of4	1of4
Control 9	0	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4
FGR 1	1	4of4	0of4	0of4	4of4	4of4	4of4	0of4	0of4	0of4
FGR 2	1	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4
FGR 3	1	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4
FGR 4	1	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4
FGR 5	1	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4
FGR 6	1	4of4	3of4	1of4	4of4	4of4	4of4	4of4	3of4	3of4


ONLY CENTRAL										
id	score	STEREOLOGY & PCR			PCR			STEREOLOGY		
		xgbTree	glmnet	nnet	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet
Control 1	0	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4
Control 2	0	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4
Control 3	0	0of4	0of4	0of4	2of4	2of4	0of4	0of4	0of4	0of4
Control 4	0	0of4	0of4	0of4	2of4	3of4	3of4	0of4	0of4	0of4
Control 5	0	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4
Control 6	0	3of4	2of4	1of4	3of4	3of4	3of4	0of4	0of4	0of4
Control 7	0	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4
Control 8	0	2of4	0of4	1of4	0of4	0of4	1of4	2of4	1of4	1of4
Control 9	0	0of4	0of4	0of4	1of4	2of4	1of4	0of4	0of4	0of4
FGR 1	1	1of4	0of4	0of4	4of4	4of4	4of4	0of4	0of4	0of4
FGR 2	1	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4
FGR 3	1	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4
FGR 4	1	0of4	0of4	0of4	0of4	0of4	0of4	1of4	0of4	0of4
FGR 5	1	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4
FGR 6	1	4of4	4of4	4of4	4of4	4of4	4of4	3of4	4of4	4of4

CENTRAL & PERIPHERAL										
id	score	STEREOLOGY & PCR			PCR			STEREOLOGY		
		xgbTree	glmnet	nnet	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet
Control 1	0	1of8	0of8	0of8	1of8	1of8	1of8	1of8	0of8	0of8
Control 2	0	0of8	0of8	0of8	0of8	0of8	0of8	0of8	0of8	0of8
Control 3	0	0of8	0of8	0of8	1of8	2of8	2of8	0of8	0of8	0of8
Control 4	0	0of8	0of8	0of8	5of8	2of8	5of8	0of8	0of8	0of8
Control 5	0	0of8	0of8	0of8	2of8	0of8	0of8	0of8	0of8	0of8
Control 6	0	3of8	1of8	0of8	6of8	7of8	6of8	0of8	0of8	0of8
Control 7	0	0of8	0of8	0of8	0of8	0of8	0of8	1of8	0of8	0of8
Control 8	0	1of8	0of8	0of8	1of8	1of8	1of8	1of8	2of8	0of8
Control 9	0	1of8	0of8	0of8	1of8	0of8	0of8	1of8	0of8	0of8
FGR 1	1	0of8	0of8	0of8	8of8	8of8	8of8	0of8	0of8	0of8
FGR 2	1	0of8	0of8	0of8	0of8	0of8	0of8	0of8	0of8	0of8
FGR 3	1	0of8	0of8	0of8	1of8	0of8	0of8	1of8	0of8	0of8
FGR 4	1	0of8	0of8	0of8	0of8	0of8	0of8	0of8	0of8	0of8
FGR 5	1	0of8	0of8	0of8	0of8	1of8	1of8	0of8	0of8	0of8
FGR 6	1	8of8	7of8	5of8	8of8	8of8	8of8	6of8	7of8	7of8

Each cell for each patient and 27 models considered (different columns) indicates how many wrong predictions were made for this patient among all 4 or 8 available samples (for example, the entry 0of4 means that 0 errors were made among 4 predictions). The cell is highlighted in

red if at least one mistake was made for the patient. Third column in the first panel corresponds to the best model, using *nnet* ML algorithm, and both stereology and PCR data for peripheral samples. This model returns only one wrong prediction out of 60 samples considered.

Supplementary Figure 1: Different interdependencies of features for stereological data.



Different interdependencies of features for Control (blue colour) and FGR (red colour) on stereological data. Each point is a separate patient measurement, each line connects all measurements for each patient. For many pairs of features, a separation between FGR cases and controls was easily seen, hence, enabling a construction of a successful predictive model.